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a  b  s  t  r  a  c  t
The  human  cytomegalovirus  (HCMV)  US2  and  US11  gene  products  hijack  mammalian  ER-associated
degradation  (ERAD)  to  induce  rapid degradation  of major  histocompatibility  class  I (MHC-I)  molecules.
The  rate-limiting  step  in  this  pathway  is  thought  to  be the  polyubiquitination  of MHC-I  by  distinct  host
ERAD  E3  ubiquitin  ligases.  TRC8  was  identiﬁed  as  the  ligase  responsible  for US2-mediated  MHC-I  degra-
dation  and  shown  to  be required  for the  cleavage-dependent  degradation  of  some  tail-anchored  proteins.
In  addition  to MHC-I,  plasma  membrane  proﬁling  identiﬁed  further  immune  receptors,  which  are  also
substrates  for  the  US2/TRC8  complex.  These  include  at least  six  integrins,  the  coagulation  factor  throm-
bomodulin  and  the  NK  cell  ligand  CD112.  US2’s  use  of  speciﬁc  HCMV-encoded  adaptors  makes  it  an
adaptable  viral  degradation  hub. US11-mediated  degradation  is  MHC-I-speciﬁc  and  genetic  screens  have
identiﬁed  TMEM129,  an  uncharacterised  RING-C2  E3  ligase,  as responsible  for US11-mediated  degrada-
tion.  In  a unique  auto-regulatory  loop,  US11  readily  responds  to changes  in cellular  expression  of  MHC-I.
Free  US11  either  rebinds  more  MHC-I  or is  itself  degraded  by  the  HRD1/SEL1L  E3 ligase  complex.  While
virally  encoded  US2  and  US11  appropriate  mammalian  ERAD,  the MHC-I  complex  also  undergoes  strin-
gent  cellular  quality  control  and  misfolded  MHC-I  is  degraded  by  the  HRD1/SEL1L  complex.  We discuss
the  identiﬁcation  and  central  role  of  E3  ubiquitin  ligases  in  ER  quality  control  and viral  degradation  of
the  MHC-I  chain.
©  2015  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
The essential role of the major histocompatibility class I (MHC-I)
antigen presentation pathway in immune detection of intracellu-
lar pathogens is emphasised by the different strategies used by
many viruses to interrupt this pathway (Hansen and Bouvier, 2009;
Randow and Lehner, 2009). The ongoing battle between viruses and
the immune system has resulted in many viruses co-evolving one
or more gene products which inhibit MHC-I presentation, with the
presumed aim of preventing viral peptide presentation by MHC-I
to cytotoxic T-lymphocytes (CTL). This is exempliﬁed in the her-
pesvirus family, with human cytomegalovirus (HCMV) providing
one of the major paradigms for viral immune evasion. As the largest
known human herpesvirus, HCMV encodes ∼170 canonical open
reading frames of which only 45 are required for viral replication,
with many of the remaining genes involved in immune evasion. The
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downside of this extensive range of viral gene products is that they
provide a smorgasbord of potential viral epitopes for MHC-I presen-
tation. In response, HCMV encodes at least four gene products that
interfere with classical MHC-I antigen presentation (Hansen and
Bouvier, 2009; Loureiro and Ploegh, 2006). HCMV  US2 and US11
promote MHC-I reverse translocation from the ER to the cytosol for
subsequent proteasomal degradation, US6 blocks TAP-dependent
peptide transport, while US3 inhibits tapasin-dependent peptide
loading and retains MHC-I in the ER. Here we review our recent
ﬁndings on the central role of ubiquitination and the identiﬁcation
of independent host ubiquitin E3 ligases used for both viral and
cellular regulation of MHC-I assembly within the ER.
2. US2 and US11 hijack mammalian ER-associated
degradation (ERAD) to target MHC-I for proteasomal
degradation in the cytosol
US2 and US11 are ER-resident type I membrane viral glyco-
proteins expressed early in HCMV infection. Upon co-translational
insertion into the ER, newly synthesised MHC-I is immediately
bound by US2 or US11 which induces its rapid degradation with a
half-life of 1–10 min. The ER is a protein-folding environment and
http://dx.doi.org/10.1016/j.molimm.2015.07.005
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is mainly devoid of proteases or an ubiquitin-proteasome system.
In a process now known as retrotranslocation or dislocation, US2
and US11 were shown to induce the reverse translocation of MHC-I
from the ER back to the cytosol where the MHC-I is deglycosylated
by protein N-glycanase (PNGase) and degraded by the proteasome
(Wiertz et al., 1996a,b).
Although retrotranslocation was ﬁrst described in the context
of US2/11-mediated MHC-I degradation, it turns out to be part of
a common cellular pathway used for the degradation of misfolded
secretory proteins from the ER—the so-called ‘ER-associated degra-
dation (ERAD)’ pathway (Olzmann et al., 2013). The ER provides a
folding environment for newly synthesised proteins and only those
proteins that acquire their native conformation and pass the ER
quality control (ERQC) checkpoint are allowed to exit the ER and
trafﬁc through the secretory pathway (Hegde and Ploegh, 2010).
ERAD therefore provides a mechanism by which misfolded pro-
teins can be safely removed from the ER by retrotranslocation back
to the cytosol and degraded by the proteasome. US2 and US11
hijack this cellular quality control pathway and ‘force-feed’ it with
folding-competent MHC-I to induce its rapid proteasomal degra-
dation. As biological tools, US2 and US11 have been invaluable for
the functional characterisation of mammalian ERAD pathways, and
allowed constructive comparisons with related degradation path-
ways in yeast. ERAD is not just responsible for the degradation of
misfolded proteins, but also plays a critical role in the regulated
turn-over of ER-resident proteins, such as the activated IP3 receptor
and the HMG-CoA reductase, squalene monooxygenase and heme
oxygenase-1 (HO-1) enzymes.
3. A central role for E3 ubiquitin ligases in the ERAD
pathway
Ubiquitination is central to ERAD and membrane-bound ERAD
E3 ubiquitin ligases form the core of the retrotranslocation machin-
ery. These ligases are surrounded by numerous ERAD factors
required for substrate recognition, dislocation and membrane
extraction. Misfolded protein substrates are recognized in the ER
by a series of chaperones including OS-9, XTP-3B, EDEM1-3 and BiP
and are recruited to the ligase via membrane components such as
SEL1L and HERP. The substrate is then ubiquitinated by the ERAD
E3 ligase and dislocated into the cytosol with the cytosolic AAA
ATPase p97/VCP supplying the energy required for dislocation and
membrane extraction. p97 is recruited to the ERAD machinery by
membrane components including Derlin-1 and UBXD8. Although
the exact nature and identity of the retrotranslocation channel
remains unclear, the membrane-bound ERAD E3 ligase and com-
ponents like Derlin-1 might form part of the retrotranslocon. The
dislocated cytosolic substrate is ﬁnally deglycosylated by p97-
associated PNGase and routed to the proteasome for degradation.
Despite the absolute requirement for ubiquitination in the
proteasome-mediated degradation of ERAD substrates, its exact
role in dislocation remains unclear. Depletion of the cognate E3
ligase with the resulting loss of ubiquitination inhibits disloca-
tion of many ERAD substrates. However, as ubiquitination only
occurs on the cytosolic side of the ER, partial retrotranslocation
must necessarily precede ubiquitination for luminal ERAD sub-
strates. Membrane extraction might again be ubiquitin-dependent
as the AAA ATPase p97 and its co-factors Ufd1/Npl4 are thought
to recognize substrates by their ubiquitin moiety. Yeast contain a
minimal ERAD machinery with only three E3 ligases: Hrd1p which
is thought to target proteins with a luminal and membrane folding
defect (ERAD-L/-M); Doa10p which targets proteins with a cyto-
solic defect (ERAD-C); and the Asi complex which targets proteins
of the nuclear envelope. The evolutionary diversiﬁcation from yeast
to higher eukaryotes greatly expanded the repertoire of ERAD E3
ligases which now include the Hrd1p homologues HRD1 and Gp78,
the Doa10p homologue MARCH6/TEB4, RNF5/RMA1, RNF170, as
well as TRC8 and TMEM129 (discussed below) and the cytosolic
E3 ligase CHIP. The driving force for this diversity and the require-
ment for an increased number of ligases is not well understood, but
increased complexity of the secretory system and cell–cell com-
munication might underlie this phenomenon. US2/11 illustrate the
increased complexity of the mammalian ERAD system. They both
hijack the mammalian ERAD machinery to induce MHC-I degra-
dation, yet these viral gene products function independently and
co-opt distinct ERAD pathways. Despite their early role in deﬁning
mammalian ERAD, the host E3 ligases hijacked by HCMV US2 and
US11 have only recently been identiﬁed.
4. The TRC8 E3 ligase ubiquitinates MHC-I and is
rate-limiting in US2-mediated degradation
To identify the E3 ligase required for US2-mediated degradation,
we used a ﬂow cytometry based siRNA screen in US2-expressing
HeLa cells using GFP-tagged MHC-I as the optical read out. Of
the 373 predicted E3 ubiquitin ligases tested, depletion of only
the TRC8 (RNF139) E3 ligase rescued MHC-I rescue from US2-
mediated degradation (Stagg et al., 2009). TRC8 encodes an ER
resident polytopic RING E3 ligase with a C-terminal RING-H2 and
a unique N-terminal sterol sensing domain (SDD) and was  previ-
ously identiﬁed as a result of a 3;8 translocation associated with
familial renal clear cell carcinoma. TRC8 binds the cytoplasmic
tail of US2 resulting in rapid MHC-I polyubiquitination, which
triggers full retrotranslocation into the cytosol and subsequent
proteasomal degradation of the MHC-I (Hsu et al., 2015; Stagg
et al., 2009) (Fig 1A). Although US2-induced degradation is lysine
dependent, lysines in the cytoplasmic tail of MHC-I are dispens-
able, suggesting TRC8 ubiquitinates the luminal domain of the
MHC-I heavy chain (Furman et al., 2003). Partial dislocation would
therefore precede ubiquitination, as seen in the dislocation of mis-
assembled MHC-I in the absence of US2/11 (Burr et al., 2013).
Interestingly, following TRC8 depletion, the presence of US2 is
insufﬁcient to retain MHC-I in the ER which escapes to the cell sur-
face, suggesting the US2-MHC interaction is transient and unable
to retain MHC-I in the ER in the absence of degradation (Stagg et al.,
2009).
A key TRC8 interaction partner is the intramembrane cleaving
aspartyl protease, signal peptide peptidase (SPP). Although SPP was
suggested to be essential for US2-mediated degradation (Loureiro
et al., 2006), neither a traditional homologous recombination-
mediated somatic cell knock-out of SPP nor CRISPR-mediated
SPP deletions in different cell lines affected US2-mediated MHC-
I degradation (Boname et al., 2014). Furthermore, the absence of
SPP did not affect the US2-TRC8 interaction. SPP does not therefore
appear to be required for the US2-mediated dislocation of MHC-I.
However, the ﬁnding of an intramembrane cleaving protease asso-
ciated with an ERAD E3 ligase does provide a potentially attractive
mechanism for ER protein turnover. In a subsequent proteomics
study we found the tail anchored (TA) protein HO-1 accumu-
lates in the absence of SPP (Boname et al., 2014). Tail anchored
proteins are inserted into the ER membrane via a C-terminal trans-
membrane domain and adopt a type II membrane orientation,
making them ideal substrates for SPP which only cleaves mem-
brane proteins with a type II orientation, a conserved feature of all
known SPP substrates. The HO-1 transmembrane domain is indeed
cleaved by SPP thereby releasing it for TRC8 dependent proteaso-
mal  degradation (Fig 1B) (Boname et al., 2014). This mechanism
of degradation is not unique to HO-1 but shared by a selection of
other TA proteins. In the absence of an extended luminal domain,
the release and degradation of these proteins might proceed with-
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Fig. 1. The US2 and US11 viral degradation hubs and their cognate host ERAD E3 ubiquitin ligases. (A) The US2/TRC8 degradation hub. US2 recruits the TRC8 E3 ligase via
its  cytosolic C-terminus. TRC8-dependent polyubiquitination of MHC-I leads to rapid retrotranslocation and degradation of the MHC-I heavy chain. In addition to MHC-I, the
US2/TRC8 degradation hub degrades a wide variety of immune receptors including at least 6 different integrin -chains, the anti-coagulation factor thrombomodulin, the
IL-12  receptor 1 chain and the NK cell ligand CD112. Whereas US2/TRC8 is sufﬁcient for the degradation of most substrates, efﬁcient degradation of CD112 requires help from
the  HCMV-encoded ‘holdase’ UL141. US2 function is independent of SPP. (B) The TRC8/SPP degradation hub mediates cleavage dependent degradation of heme oxygenase-
1  (HO-1). SPP-mediated cleavage of the HO-1 transmembrane domain releases HO-1 from the membrane and induces TRC8-dependent ubiquitination and proteasomal
degradation. This pathway is used by other tail-anchored proteins. (C) The US11/TMEM129 degradation hub. US11-bound MHC-I is rapid ubiquitinated by the TMEM129 E3
ligase  and subsequently retrotranslocated to the cytosol for proteasomal degradation. TMEM129 is recruited to US11 via Derlin-1. US11 is not itself a substrate for TMEM129,
but  is either recycled to bind another MHC-I molecule, or is degraded by the HRD1/SEL1L ERAD complex in an auto-regulation loop. In this way, HRD1-mediated degradation
of  ‘free US11’ buffers US11 levels to the MHC-I client load.
out the need of a retrotranslocation channel with ubiquitination
sufﬁcient to drive their post-cleavage proteasomal degradation.
Intramembrane cleavage by SPP or its cousin RHBDL4 might also
aid in the degradation of proteins with a more complex membrane
orientation including the transcription factor XBP1u, though their
mode of extraction remains unclear (Chen et al., 2014; Fleig et al.,
2012).
TRC8 function likely extends beyond the degradation of TA
proteins. Its sterol sensing domain suggests an involvement in
membrane lipid homeostasis, though the role of TRC8 in the
processing of SREBP transcription factors and sterol-induced degra-
dation of HMG-CoA reductase remains controversial (Irisawa et al.,
2009; Jo et al., 2011; Lee et al., 2010; Tsai et al., 2012). The study of
US2 has therefore uncovered a novel branch of mammalian ERAD
with an E3 ligase involved in channel-independent degradation and
lipid homeostasis.
5. TMEM129, a non-classical RING E3 ligase, mediates
HCMV US11-induced MHC-I ubiquitination
A requirement for ubiquitin for US11 activity was demonstrated
in a temperature sensitive E1 ubiquitin activating enzyme cell line
but the role of substrate ubiquitination was  confusing as US11 can
target a lysine-less MHC-I molecule (Hassink et al., 2006; Kikkert
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et al., 2001). The recognition that ubiquitination can occur on non-
lysine residues, including serine/threonine and cysteine, provided
a potential solution to this problem (Cadwell and Coscoy, 2005;
Wang et al., 2009). The E3 ligase responsible however, remained
elusive. An interaction between US11 and the HRD1 retrotranslo-
cation component SEL1L led to suggestions that HRD1 might be
the host E3 ligase for US11 (Mueller et al., 2006). However, nei-
ther HRD1 depletion nor expression of a HRD1 dominant-negative
mutant rescued US11-induced MHC-I degradation. We  were puz-
zled that our siRNA ubiquitome screen which found TRC8 as the E3
ligase responsible for US2-mediated MHC-I dislocation, only identi-
ﬁed the E2 ubiquitin conjugase (Ube2J2) essential for US11 activity,
but failed to identify any E3 ligase (van den Boomen et al., 2014).
Subsequent progress toward the identiﬁcation of the host E3
ligase responsible for US11-induced degradation came from two
related genetic approaches. We  performed a forward genetic screen
in the near-haploid human KBM7 cell line expressing US11 and
identiﬁed an uncharacterised gene TMEM129 as both essential
and rate-limiting for US11-mediated MHC-I degradation (van den
Boomen et al., 2014), while a related study identiﬁed TMEM129 in
a genome wide shRNA screen for US11-induced degradation (van
de Weijer et al., 2014). TMEM129 is an ER-resident membrane pro-
tein conserved from humans to the single cell organism Capsaspora
owczarzaki,  with no orthologue in yeast. Its cytoplasmic C-terminus
contains a unique and highly conserved cysteine-rich region with
similarity to the RING domain of E3 ubiquitin ligases. The classical
ubiquitin RING domain consists of interspersed cysteine and histi-
dine residues in a cross-brace motif that coordinates two zinc atoms
and forms a binding platform for the E2 ubiquitin conjugase. The
putative RING of TMEM129 is unusual as it predicts elongated loops
not seen in other RING domains and has only cysteine residues, but
no histidine for zinc coordination. From the bioinformatics stand-
point it was never classiﬁed as a putative ubiquitin E3 ligase ‘RING’,
which explains why we were unable to ﬁnd it in our initial siRNA
ubiquitome screen of predicted E3 ligases.
In vitro we  showed the TMEM129 RING has autoubiquitination
activity, the hallmark of ubiquitin RINGs and TMEM129-deﬁcient
cells show a loss of US11-induced MHC-I ubiquitination as well as
retrotranslocation and proteasomal degradation (van den Boomen
et al., 2014). TMEM129 is therefore a bona ﬁde RING E3 ligase
and the central component of US11-induced MHC-I degradation
(Fig 1C). Interestingly, whereas depletion of TRC8 in the US2 sys-
tem allows MHC-I to escape to the cell surface, in the absence of
TMEM129, MHC-I accumulates in the ER of US11+ cells. US11 there-
fore not only acts as degradation factor for MHC-I but also as an
ER retention factor, as originally seen with a US11 Q192L mutant
(Lilley et al., 2003). We  found that TMEM129 is recruited to US11
via the rhomboid pseudo-protease Derlin-1, which bridges US11
to TMEM129 and binds US11 via the polar glutamine residue 192
(Q192) in the US11 transmembrane domain and TMEM129 via its
transmembrane region (Lilley and Ploegh, 2004; van den Boomen
et al., 2014). Like TMEM129-deﬁcient cells, Derlin-1-deﬁcient
cells fail to assemble a functional US11-TMEM129 degradation
complex and lack US11-induced MHC-I degradation. Studies of
US11-mediated degradation have therefore not only yielded insight
into the role of ubiquitination in the degradation of membrane pro-
teins from the ER, but identiﬁed a novel and unique E3 ligase which
functions in a previously uncharacterised Derlin-1 dependent ERAD
pathway.
6. The short tail of US11 allows its escape from
TMEM129-mediated degradation
US11 combines both ER retention and degradation functions.
This dual function allows US11 to prevent MHC-I surface expres-
sion during times when the client load is high and the TMEM129
E3 ligase is limiting, as might occur during early HCMV infection
when MHC-I expression is elevated by interferon signalling. The
strong interaction between MHC-I and US11 retains MHC-I in the
ER but poses a potential threat to US11, which must avoid self-
destruction via TMEM129. Co-degradation seemed unlikely as the
half-life of US11 of ∼1 h is considerably longer than the very short
half-life of US11-associated MHC-I (1–5 min). To avoid TMEM129-
induced US11 degradation, US11 has a short cytoplasmic tail largely
devoid of ubiquitin acceptor residues, which contrasts with the
longer, lysine-rich MHC-I tail. A tail swap between US11 and
MHC-I reverses their fate, inducing a rapid TMEM129-dependent
degradation of US11, leaving MHC-I completely unaffected (van
den Boomen et al., 2014). US11 may  therefore act as a ‘pseudo-
substrate’; it recruits the E3 ligase but deﬂects ubiquitination onto
its MHC-I client. The subsequent degradation of MHC-I frees US11
to bind the next MHC-I molecule and restarts the degradation cycle.
Avoiding self-degradation, either through a short cytosolic tail, or
a tail devoid of ubiquitin acceptor residues might be a common
feature for viral immune evasins that directly or indirectly interact
with an E3 ligase. Such a strategy includes the viral proteins US2
and US3, and might extend to select host ERAD factors including
Herp and SEL1L.
7. An auto-regulatory control loop ﬁne tunes US11 activity
and allows it to buffer changes in MHC-I expression
Although US11 avoids ubiquitination by TMEM129, in the
absence of MHC-I it is itself unstable and degraded by the clas-
sical ERAD E3 ligase HRD1, which is also part of the US11 complex.
Depletion of HRD1 or its retrotranslocation component SEL1L
increases US11 expression without affecting MHC-I degradation.
There are therefore two ongoing degradation processes within the
US11 complex—the rapid degradation of MHC-I by TMEM129 and
the slow turnover of US11 by the HRD1/SEL1L complex (Fig 1C).
This observation explains a conundrum of US11-mediated degra-
dation, that US11 binds SEL1L, while the TMEM129 E3 ligase does
not. Why  might this complex arrangement have evolved?
The HRD1/SEL1L complex has a well-deﬁned function in the
turnover of misassembled complexes of membrane proteins,
including misassembled TCR and CD3, and the turn-over of US11
must be seen within this context. US11 binds MHC-I in a stable com-
plex as seen in the ER retention of MHC-I in TMEM129-deﬁcient
cells. Following the TMEM129-dependent degradation of MHC-I,
we propose unpaired or ‘free’ US11 either re-binds a fresh MHC-I or
exposes a degron that overlaps with the MHC  binding site. Unpaired
US11 is inherently unstable and the US11 degron is recognized by
SEL1L, leading to HRD1-dependent degradation. In support of this
model, US11 expression levels are markedly increased following
expression of a soluble MHC-I which is not a substrate for TMEM129
(van den Boomen et al., 2014). Binding of US11 by soluble MHC-I
masks its degron, increasing its stability. Similarly TMEM129 deple-
tion leads to a marked increase in US11 expression. This is not
because US11 is a TMEM129 substrate but because the MHC-I is
no longer degraded and therefore binds US11, resulting in a stable
US11-MHC-I complex. In this way, the degradation of US11 pro-
vides an autoregulatory control loop, which buffers US11 against
the amount of MHC-I present in the cell. When a large amount
of MHC-I is present, it will bind US11, and when MHC-I levels
decrease, free US11 is degraded by HRD1 (Fig 1C).
Therefore this HRD1 mediated degradation of US11 ﬁne-tunes
US11-mediated degradation, allowing US11 to respond to changes
in MHC-I concentration in the ER. If MHC-I levels increase, for exam-
ple due to interferon signalling, US11 levels will concomitantly
increase and instantly retain and destroy the MHC-I. Conversely
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when MHC-I levels are low, US11 expression will decrease. This
prevents an accumulation of unnecessary ‘free’ US11 in the ER and
increases the probability of TMEM129 to ﬁnd US11-MHC-I com-
plexes and induce MHC-I degradation. This ﬁne-tuning of MHC-I
degradation by targeted degradation of ‘free’ US11 is reminiscent
of ‘ERAD tuning’, a process in which components of the ERAD
machinery such as HERP and EDEM1 are degraded or removed
in the absence of protein substrates (Bernasconi et al., 2013; Cali
et al., 2008). Viral induced degradation therefore resembles host
cell ERAD in several aspects.
8. The US2/TRC8 complex acts as a multifunctional viral
degradation hub
The hijacking of host ERAD E3 ligases by HCMV US2 and US11
provides HCMV with a powerful mechanism to deplete the host
cell of a key molecule essential for immune surveillance. The same
strategy could be used by HCMV to degrade additional immune
receptors. US2 degrades components of the MHC-II complex as well
as the MHC-like molecule HFE (Ben-Arieh et al., 2001; Tomazin
et al., 1999). To identify additional US2/11 substrates we took an
unbiased proteomic proﬁling approach we term ‘plasma membrane
proﬁling’ (Hsu et al., 2015). While US11 is remarkably MHC-I spe-
ciﬁc, analysis of US2-expressing cells suggested the degradation
of MHC-like molecules is only the tip of the iceberg. It turns out
US2 targets a host of unrelated cell surface proteins including a
wide range of  integrins, the anti-coagulation factor thrombo-
modulin, the IL-12 receptor 1 chain and the NK cell ligand CD112
(Fig 1A). Degradation of all these substrates proceeds via the same
TRC8 pathway as deﬁned for MHC-I. While the US2/TRC8 complex
alone is able to degrade the majority of substrates, we also uncov-
ered an interesting example of cooperation between two HCMV
viral proteins in the degradation of the NK cell ligand CD112 which
required both US2 and HCMV UL141. UL141 retains CD112 in the ER
from where it is targeted for degradation by the US2/TRC8 complex
(Fig 1A) (Hsu et al., 2015; Prod’homme et al., 2010).
Through its appropriation of TRC8, US2 therefore functions as
a virus-encoded degradation hub. US2’s ability to target a vari-
ety of structurally distinct substrates makes it a highly adaptable
degradation factor whose substrate speciﬁcity can be altered by the
expression of different retention factors. Whereas immediate early
expression of US3, for instance, enables US2 to initially focus on
MHC-I degradation and avoid early T-cell recognition, late expres-
sion of UL141 might switch substrate speciﬁcity toward CD112 to
prevent NK cell killing—an essential function once MHC  levels are
decreased. Continuous degradation of  integrins might meanwhile
prevent infected dendritic cells from moving to the draining lymph
node during virus reactivation. US2 thus forms a multifunctional
and multifactorial viral degradation hub that hijacks mammalian
TRC8-dependent ERAD to target multiple angles of anti-viral immu-
nity.
9. HRD1 mediates endogenous quality control of
misassembled MHC-I heavy chains
Under normal physiological conditions, in the absence of viral
infection, the MHC-I heterotrimer undergoes a stringent quality
control, and those molecules which fail to attain their native state
are degraded via ERAD. Somewhat surprisingly, neither TRC8 nor
TMEM129 are used to target misfolded MHC-I for degradation. In an
independent siRNA screen, we identiﬁed the HRD1-SEL1L E3 ligase
complex and the E2 Ube2J1 as required for degradation of misfolded
MHC-I (Burr et al., 2011). Early recognition of the misfolded MHC-I
heavy chain is mediated by the ER mannosidase EDEM1 and lectins
OS9 and XTP3B (Burr et al., 2013). US2 and US11 do not there-
fore accelerate an endogenous pathway for MHC-I clearance but
function as MHC-I-speciﬁc recruitment factors that by-pass early
recognition steps within the ERAD process and force-feed a dif-
ferent ligase complex with ‘folding-competent’ MHC-I. However,
HRD1-mediated degradation of MHC-I does share some character-
istics with the US2 and US11 pathways. Like US11, HRD1 can for
example degrade a lysine-less MHC-I molecule, and like US2 this
degradation process does not require a cytoplasmic tail (Burr et al.,
2013; Furman et al., 2003; Hassink et al., 2006). Indeed, mapping
of MHC-I ubiquitination showed preferential HRD1-dependent ubi-
quitination on lysine residues of the MHC-I luminal domain (Burr
et al., 2013).
The study of MHC-I degradation by viral and endogenous
proteins has therefore identiﬁed three independent branches of
mammalian ERAD, each with its characteristic E3 ubiquitin ligase,
which emphasises the complexities of this important quality con-
trol pathway and provided mechanistic insight into the ongoing
battle between viral infection and immune detection.
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